SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Reith Christina)
 

Sökning: WFRF:(Reith Christina) > Effects of Lowering...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003256naa a2200457 4500
001oai:DiVA.org:uu-231243
003SwePub
008140905s2014 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2312432 URI
0247 a https://doi.org/10.1681/ASN.20130909652 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Haynes, Richard4 aut
2451 0a Effects of Lowering LDL Cholesterol on Progression of Kidney Disease
264 1c 2014
338 a print2 rdacarrier
520 a Lowering LDL cholesterol reduces the risk of developing atherosclerotic events in CKD, but the effects of such treatment on progression of kidney disease remain uncertain. Here, 6245 participants with CKD (not on dialysis) were randomly assigned to simvastatin (20 mg) plus ezetimibe (10 mg) daily or matching placebo. The main prespecified renal outcome was ESRD (defined as the initiation of maintenance dialysis or kidney transplantation). During 4.8 years of follow-up, allocation to simvastatin plus ezetimibe resulted in an average LDL cholesterol difference (SEM) of 0.96 (0.02) mmol/L compared with placebo. There was a nonsignificant 3% reduction in the incidence of ESRD (1057 [33.9%] cases with simvastatin plus ezetimibe versus 1084 [34.6%] cases with placebo; rate ratio, 0.97; 95% confidence interval [95% CI], 0.89 to 1.05; P=0.41). Similarly, allocation to simvastatin plus ezetimibe had no significant effect on the prespecified tertiary outcomes of ESRD or death (1477 [47.4%] events with treatment versus 1513 [48.3%] events with placebo; rate ratio, 0.97; 95% CI, 0.90 to 1.04; P=0.34) or ESRD or doubling of baseline creatinine (1189 [38.2%] events with treatment versus 1257 [40.2%] events with placebo; rate ratio, 0.93; 95% CI, 0.86 to 1.01; P=0.09). Exploratory analyses also showed no significant effect on the rate of change in eGFR. Lowering LDL cholesterol by 1 mmol/L did not slow kidney disease progression within 5 years in a wide range of patients with CKD.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
7001 a Lewis, David4 aut
7001 a Emberson, Jonathan4 aut
7001 a Reith, Christina4 aut
7001 a Agodoa, Lawrence4 aut
7001 a Cass, Alan4 aut
7001 a Craig, Jonathan C.4 aut
7001 a de Zeeuw, Dick4 aut
7001 a Feldt-Rasmussen, Bo4 aut
7001 a Fellström, Bengtu Uppsala universitet,Njurmedicin4 aut0 (Swepub:uu)bengfell
7001 a Levin, Adeera4 aut
7001 a Wheeler, David C.4 aut
7001 a Walker, Rob4 aut
7001 a Herrington, William G.4 aut
7001 a Baigent, Colin4 aut
7001 a Landray, Martin J.4 aut
7102 a Uppsala universitetb Njurmedicin4 org
7730 t Journal of the American Society of Nephrologyg 25:8, s. 1825-1833q 25:8<1825-1833x 1046-6673x 1533-3450
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-231243
8564 8u https://doi.org/10.1681/ASN.2013090965

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy